《公司业绩》欧舒丹(00973.HK)第二季收入跌8.6%至3.4亿欧元
欧舒丹(00973.HK)公布,至9月底止第二季度表现,总销售净额为3.42亿欧元(下同),按年跌8.59%,按固定汇率计算的跌幅为4.5%。
集团的销售势头在第二季度显着改善,销售下降幅度收窄至-4.5%,而2021财年第一季度则为-22.2%。
期内,中国、台湾及俄罗斯录得的销售增长,分别增长35.4%、18.8%及11.9%。网上渠道增长64.6%。
上半年,总销售净额为6.17亿元,按年跌15.2%,按固定汇率计算的跌幅为13.1%。同店销售录10.4%跌幅。至9月底止,自营零售店为1,569间,较去年同期减少39间。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.